Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial)

This is a single-arm, open-label, phase II study evaluating the clinical outcomes of local therapy (surgery or radiotherapy) to the primary tumor in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) who have achieved disease control following first-line treatment with the FLAURA2 regimen (osimertinib plus platinum-based chemotherapy). The primary objective is to assess the median progression-free survival (PFS) after local therapy.

Trial Details

NCT ID

NCT07073365

Phase

PHASE2

Sponsor

Pusan National University Hospital

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Local Therapy (Surgery or Radiotherapy)

Locations (sample)

Busan, South Korea|35.10168,129.03004

Key Eligibility Criteria

Participants must meet all of the following criteria to be eligible:
Age ≥ 20 years at the time of consent.
Histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC).
Presence of activating EGFR mutation (exon 19 deletion or L858R).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →